The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.

På svenska

Author

  • Nina Mononen
  • Eija H Seppälä
  • Priya Duggal
  • Ville Autio
  • Tarja Ikonen
  • Pekka Ellonen
  • Juha Saharinen
  • Janna Saarela
  • Mauno Vihinen
  • Teuvo L J Tammela
  • Olli Kallioniemi
  • Joan E Bailey-Wilson
  • Johanna Schleutker
Show all

Summary, in English

Several candidate genes along androgen pathway have been suggested to affect prostate cancer risk but no single gene seems to be overwhelmingly important for a large fraction of the patients. In this study, we first screened for variants in candidate genes and then chose to explore the association between 18 variants and prostate cancer risk by genotyping DNA samples from unselected (n = 847) and familial (n = 121) prostate cancer patients and population controls (n = 923). We identified a novel single nucleotide polymorphism (SNP) in the CYP19A1 gene, T201M, with a mild significant association with prostate cancer [odds ratio (OR), 2.04; 95% confidence interval (95% CI), 1.03-4.03; P = 0.04]. Stratified analysis revealed that this risk was most apparent in patients with organ-confined (T(1)-T(2)) and low-grade (WHO grade 1) tumors (OR, 5.42; 95% CI, 2.33-12.6; P < 0.0001). In contrast, CYP17A1 -34T>C alteration was associated with moderate to poorly differentiated (WHO grade 2-3) organ-confined disease (OR, 1.42; 95% CI, 1.09-1.83; P = 0.007). We also tested a multigenic model of prostate cancer risk by calculating the joint effect of CYP19A1 T201M with five other common SNPs. Individuals carrying both the CYP19A1 and KLK3 -252A>G variant alleles had a significantly increased risk for prostate cancer (OR, 2.87; 95% CI, 1.10-7.49; P = 0.03). In conclusion, our results suggest that several SNPs along the androgen pathway, especially in CYP19A1 and CYP17A1, may influence prostate cancer development and progression. These genes may have different contributions to distinct clinical subsets as well as combinatorial effects in others illustrating that profiling and joint analysis of several genes along each pathway may be needed to understand genetic contributions to prostate cancer etiology.

Publishing year

2006

Language

English

Pages

743-747

Publication/Series

Cancer Research

Volume

66

Issue

2

Document type

Journal article

Publisher

American Association for Cancer Research Inc.

Topic

  • Medical Genetics

Keywords

  • Androgens: biosynthesis
  • Aromatase: genetics
  • Prostatic Neoplasms: genetics
  • Prostatic Neoplasms: physiopathology
  • Steroid 17-alpha-Hydroxylase: genetics

Status

Published

ISBN/ISSN/Other

  • ISSN: 1538-7445